S&P 500   4,270.40 (-0.41%)
DOW   33,331.74 (-0.52%)
QQQ   359.57 (+0.36%)
AAPL   173.20 (+1.16%)
MSFT   318.36 (+0.83%)
META   303.71 (+1.17%)
GOOGL   132.97 (+1.61%)
AMZN   128.66 (+1.21%)
TSLA   249.53 (-0.28%)
NVDA   447.20 (+2.81%)
NIO   8.78 (-2.88%)
BABA   86.14 (-0.69%)
AMD   102.87 (+0.05%)
T   14.80 (-1.46%)
F   12.25 (-1.37%)
MU   67.61 (-0.62%)
CGC   0.73 (-6.17%)
GE   108.74 (-1.64%)
DIS   81.23 (+0.22%)
AMC   7.90 (-1.13%)
PFE   33.61 (+1.33%)
PYPL   58.22 (-0.41%)
NFLX   378.40 (+0.21%)
S&P 500   4,270.40 (-0.41%)
DOW   33,331.74 (-0.52%)
QQQ   359.57 (+0.36%)
AAPL   173.20 (+1.16%)
MSFT   318.36 (+0.83%)
META   303.71 (+1.17%)
GOOGL   132.97 (+1.61%)
AMZN   128.66 (+1.21%)
TSLA   249.53 (-0.28%)
NVDA   447.20 (+2.81%)
NIO   8.78 (-2.88%)
BABA   86.14 (-0.69%)
AMD   102.87 (+0.05%)
T   14.80 (-1.46%)
F   12.25 (-1.37%)
MU   67.61 (-0.62%)
CGC   0.73 (-6.17%)
GE   108.74 (-1.64%)
DIS   81.23 (+0.22%)
AMC   7.90 (-1.13%)
PFE   33.61 (+1.33%)
PYPL   58.22 (-0.41%)
NFLX   378.40 (+0.21%)
S&P 500   4,270.40 (-0.41%)
DOW   33,331.74 (-0.52%)
QQQ   359.57 (+0.36%)
AAPL   173.20 (+1.16%)
MSFT   318.36 (+0.83%)
META   303.71 (+1.17%)
GOOGL   132.97 (+1.61%)
AMZN   128.66 (+1.21%)
TSLA   249.53 (-0.28%)
NVDA   447.20 (+2.81%)
NIO   8.78 (-2.88%)
BABA   86.14 (-0.69%)
AMD   102.87 (+0.05%)
T   14.80 (-1.46%)
F   12.25 (-1.37%)
MU   67.61 (-0.62%)
CGC   0.73 (-6.17%)
GE   108.74 (-1.64%)
DIS   81.23 (+0.22%)
AMC   7.90 (-1.13%)
PFE   33.61 (+1.33%)
PYPL   58.22 (-0.41%)
NFLX   378.40 (+0.21%)
S&P 500   4,270.40 (-0.41%)
DOW   33,331.74 (-0.52%)
QQQ   359.57 (+0.36%)
AAPL   173.20 (+1.16%)
MSFT   318.36 (+0.83%)
META   303.71 (+1.17%)
GOOGL   132.97 (+1.61%)
AMZN   128.66 (+1.21%)
TSLA   249.53 (-0.28%)
NVDA   447.20 (+2.81%)
NIO   8.78 (-2.88%)
BABA   86.14 (-0.69%)
AMD   102.87 (+0.05%)
T   14.80 (-1.46%)
F   12.25 (-1.37%)
MU   67.61 (-0.62%)
CGC   0.73 (-6.17%)
GE   108.74 (-1.64%)
DIS   81.23 (+0.22%)
AMC   7.90 (-1.13%)
PFE   33.61 (+1.33%)
PYPL   58.22 (-0.41%)
NFLX   378.40 (+0.21%)
Top-Rated StocksTop-Rated
NASDAQ:ZNTL

Zentalis Pharmaceuticals (ZNTL) Stock Forecast, Price & News

$19.52
-0.54 (-2.69%)
(As of 01:39 PM ET)
Compare
Today's Range
$19.45
▼
$20.26
50-Day Range
$19.63
▼
$28.25
52-Week Range
$15.55
▼
$31.46
Volume
435,429 shs
Average Volume
699,302 shs
Market Capitalization
$1.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.50
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Zentalis Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
142.7% Upside
$47.50 Price Target
Short Interest
Bearish
15.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of Zentalis Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$125,250 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.79) to ($4.64) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

712th out of 969 stocks

Pharmaceutical Preparations Industry

342nd out of 453 stocks

See Top Rated MarketRank™ Stocks Here

ZNTL stock logo

About Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics: and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

ZNTL Price History

ZNTL Stock News Headlines

September 26, 2023 | americanbankingnews.com
Analysts Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Price Target at $47.50
September 26, 2023 | americanbankingnews.com
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Buy" by Brokerages
October 2, 2023 | Porter and Company (Ad)
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI"
If this tech goes mainstream, it could destroy the oil and gas industry, the clean energy sector, and the billionaires who profit from it…
September 14, 2023 | finance.yahoo.com
Director Jan Skvarka Sells 5,000 Shares of Zentalis Pharmaceuticals Inc (ZNTL)
September 6, 2023 | finance.yahoo.com
Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 24, 2023 | seekingalpha.com
Zentalis: A Buy As Small Molecule Trials Continue To Advance
August 11, 2023 | msn.com
Wells Fargo Maintains Zentalis Pharmaceuticals (ZNTL) Overweight Recommendation
August 11, 2023 | msn.com
Wedbush Reiterates Zentalis Pharmaceuticals (ZNTL) Outperform Recommendation
October 2, 2023 | Porter and Company (Ad)
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI"
If this tech goes mainstream, it could destroy the oil and gas industry, the clean energy sector, and the billionaires who profit from it…
August 9, 2023 | finance.yahoo.com
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
August 3, 2023 | finanznachrichten.de
ZENTALIS PHARMACEUTICALS: Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 1, 2023 | finance.yahoo.com
Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer
July 6, 2023 | msn.com
Zentalis Pharmaceuticals (ZNTL) Price Target Increased by 7.94% to 51.31
June 22, 2023 | msn.com
Matrix Capital Infuses $108 Million Into Zentalis Toward Promising Cancer Therapeutics
June 21, 2023 | msn.com
Here’s a Look at Zentalis Stock’s (NASDAQ:ZNTL) Significant Insider Trade
June 15, 2023 | markets.businessinsider.com
Zentalis Pharma Prices Underwritten Stock Offering
June 7, 2023 | msn.com
Wedbush Reiterates Zentalis Pharmaceuticals (ZNTL) Prior Recommendation
June 6, 2023 | finance.yahoo.com
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
June 2, 2023 | finance.yahoo.com
Why Shares of Zentalis Pharmaceuticals Dropped This Week
May 30, 2023 | msn.com
Zentalis gives up gains from ovarian cancer candidate data; down 11%
May 30, 2023 | markets.businessinsider.com
Stifel Nicolaus Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
May 29, 2023 | markets.businessinsider.com
SVB Securities Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)
May 26, 2023 | msn.com
Wedbush Maintains Zentalis Pharmaceuticals (ZNTL) Outperform Recommendation
May 26, 2023 | msn.com
Zentalis Gears Up for Phase 3 Study of Azenosertib after Positive Phase 1b Outcomes
May 25, 2023 | finance.yahoo.com
Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting
May 25, 2023 | markets.businessinsider.com
Stifel Nicolaus Sticks to Its Buy Rating for Zentalis Pharmaceuticals (ZNTL)
May 23, 2023 | finance.yahoo.com
Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combinations
See More Headlines
Receive ZNTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ZNTL Company Calendar

Last Earnings
8/09/2023
Today
10/02/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZNTL
CUSIP
N/A
CIK
1725160
Web
www.zentalis.com
Phone
212-433-3791
Fax
N/A
Employees
156
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$47.50
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+138.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($4.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-236,810,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-64.37%
Return on Assets
-52.33%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.90
Quick Ratio
10.90

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.61 per share
Price / Book
2.62

Miscellaneous

Outstanding Shares
70,610,000
Free Float
66,302,000
Market Cap
$1.41 billion
Optionable
Not Optionable
Beta
1.87
Elon Musk's Next Move Cover
Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Kimberly Lynn Blackwell M.D. (Age 54)
    CEO & Director
    Comp: $1.12M
  • Mr. Cameron S. Gallagher M.B.A. (Age 53)
    Co-Founder, Pres & Director
    Comp: $767.69k
  • Dr. Kevin D. Bunker Ph.D. (Age 51)
    Co-Founder & Chief Scientific Officer
    Comp: $822.33k
  • Ms. Melissa B. Epperly M.B.A.Ms. Melissa B. Epperly M.B.A. (Age 45)
    CFO & Treasurer
    Comp: $721.64k
  • Ms. Andrea Paul J.D. (Age 42)
    Gen. Counsel & Corp. Sec.
    Comp: $668.2k
  • Dr. Carrie Brownstein M.D. (Age 53)
    Chief Medical Officer
    Comp: $755.06k
  • Ms. Iris Roth Ph.D. (Age 53)
    Chief Operating Officer
  • Dr. Mark Lackner Ph.D. (Age 56)
    Chief Translational Officer & Head of Biomarker Strategy
  • Ms. Kimberly Freeman
    Chief Strategy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ZNTL Stock - Frequently Asked Questions

Should I buy or sell Zentalis Pharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zentalis Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZNTL shares.
View ZNTL analyst ratings or view top-rated stocks.

What is Zentalis Pharmaceuticals' stock price forecast for 2023?

7 brokers have issued 1 year price objectives for Zentalis Pharmaceuticals' shares. Their ZNTL share price forecasts range from $27.00 to $70.00. On average, they predict the company's stock price to reach $47.50 in the next twelve months. This suggests a possible upside of 138.1% from the stock's current price.
View analysts price targets for ZNTL or view top-rated stocks among Wall Street analysts.

How have ZNTL shares performed in 2023?

Zentalis Pharmaceuticals' stock was trading at $20.14 at the beginning of the year. Since then, ZNTL shares have decreased by 0.9% and is now trading at $19.95.
View the best growth stocks for 2023 here.

When is Zentalis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our ZNTL earnings forecast.

How were Zentalis Pharmaceuticals' earnings last quarter?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) issued its quarterly earnings data on Wednesday, August, 9th. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($1.03) by $0.82. During the same period in the prior year, the firm posted ($1.34) earnings per share.

What ETFs hold Zentalis Pharmaceuticals' stock?

ETFs with the largest weight of Zentalis Pharmaceuticals (NASDAQ:ZNTL) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Zentalis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zentalis Pharmaceuticals investors own include Esperion Therapeutics (ESPR), Zogenix (ZGNX), AbbVie (ABBV), Advanced Micro Devices (AMD), BioMarin Pharmaceutical (BMRN), Bristol-Myers Squibb (BMY), Clovis Oncology (CLVS), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and Phillips 66 (PSX).

When did Zentalis Pharmaceuticals IPO?

(ZNTL) raised $131 million in an initial public offering (IPO) on Friday, April 3rd 2020. The company issued 7,700,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.

What is Zentalis Pharmaceuticals' stock symbol?

Zentalis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZNTL."

How do I buy shares of Zentalis Pharmaceuticals?

Shares of ZNTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zentalis Pharmaceuticals' stock price today?

One share of ZNTL stock can currently be purchased for approximately $19.95.

How much money does Zentalis Pharmaceuticals make?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) has a market capitalization of $1.41 billion. The company earns $-236,810,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis.

How many employees does Zentalis Pharmaceuticals have?

The company employs 156 workers across the globe.

How can I contact Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals' mailing address is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. The official website for the company is www.zentalis.com. The company can be reached via phone at 212-433-3791 or via email at thoffmann@soleburytrout.com.

This page (NASDAQ:ZNTL) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -